pp-100 Tablets

Indication: Moderate to severe active rheumatoid arthritis and other autoimmune/inflammatory conditions including atopic dermatitis and prurigo nodularis in adult populations Clinical stage: Clinical development — Phase 2 multi‑center trial recruiting with prior Phase 1a/1b studies ongoing Modality: Small molecule protein degrader (Cereblon‑based CDAC) Mechanism / Target: Interleukin‑1 receptor‑associated kinase 4 (IRAK4) degradation to inhibit IL‑1R/TLR signaling and downstream inflammatory pathways Route / form: Oral administration (expected oral small‑molecule formulation) Differentiation: First‑in‑class IRAK4 degrader offering complete elimination of kinase and scaffold function to broadly suppress inflammatory signaling with potential advantages over conventional IRAK4 inhibitors